neuroClues
neuroClues is a portable, CE-marked class IIa medical device that records eye movements at 400 frames per second per eye and computes objective, reproducible oculomotor biomarkers in about ten minutes to support neurological assessment.
What is neuroClues?
neuroClues is an eye-movement recording platform built for everyday clinical neurology, and a CE-marked class IIa medical device under the European MDR. Its stated indication is to record, view and analyse eye movements in support of identifying visual tracking impairment in human subjects from five years old.
The platform has three connected parts. The Lab is a portable headset mounted on an adjustable stand; its patented cone creates a standardised, light-free recording environment and holds the patient at a fixed distance, while the arm allows recording in an ecological posture, wheelchair included. Two infrared cameras, one per eye, capture at 400 frames per second across an inspection range of 23.6 degrees vertically and 40 degrees horizontally, and no patient calibration is required. The App runs on a dedicated computer physically wired to the Lab and drives recording, analysis and interpretation. The Cloud acts as a remote database, enabling multi-user and multi-site work and pushing software updates.
The workflow has three steps: pick the protocols that match the clinical question, record for roughly ten minutes, then interpret the output. Proprietary AI algorithms compute the biomarkers and display them next to reference ranges drawn from systematic literature reviews, alongside position and velocity timecourses and the eye-movement videos. The app then assembles a PDF report mixing quantitative results with the clinician's own observations. Six paradigms are available, from visually guided saccades and antisaccades to pursuit, fixation and optokinetic nystagmus, and protocols can be customised in the app or built to order.
The pitch is to replace the subjective follow-my-finger test, essentially unchanged for sixty years, with quantified and reproducible data. The company cites the World Health Organization's 2025 figure of one person in three affected by a neurological disorder, one patient in five still misdiagnosed, and 65% of affected neurons already lost by the time a diagnosis lands. Documented use cases are the differential diagnosis of atypical parkinsonian syndromes and the objective quantification of cerebellar syndrome. The exam can be delegated to an assistant or a nurse, and is covered by an existing reimbursement code in several countries including France and Belgium.
What it does
- Record binocular eye movements at 400 frames per second per eye, with no patient calibration
- Compute objective oculomotor biomarkers automatically: latency, error rate, peak velocity and gain
- Display every result against reference ranges derived from systematic literature reviews
- Return position and velocity timecourses plus the eye-movement video for each recording
- Generate a complete patient report in PDF, combining quantitative results with clinical notes
- Run six standard paradigms, from visually guided saccades to optokinetic nystagmus
- Organise subjects into shareable projects and track their history over time across sites
When to use neuroClues / When not to
A quick filter to help you decide if neuroClues is the right fit.
When to use neuroClues
- Neurologists in hospitals and private practice who need objective data for the differential diagnosis of atypical parkinsonian syndromes
- Neuro-ophthalmology and neurorehabilitation teams assessing oculomotor and visual tracking impairment
- Clinical researchers and cohort investigators building normative or longitudinal oculomotor datasets
- Nurses and clinical assistants, since the ten-minute acquisition is explicitly designed to be delegated
- Practice and department managers weighing an all-included leasing model tied to an existing reimbursement code
When not to use neuroClues
- Patients or consumers looking for self-assessment: this is a regulated medical device operated by healthcare professionals
- Anyone wanting a downloadable app: there is no iOS or Android application and no individual sign-up
- Buyers outside the European Union, where the device is not yet on sale pending regulatory approvals
- Teams expecting transparent online pricing or self-service purchase: access runs through a demo and a sales conversation
- Developers hoping to embed the technology: no public API and no third-party integrations are announced
How to use neuroClues
A typical end-to-end flow, from setup to results.
- Book a 30-minute online demo with a neuroClues specialist, or reach the team through the contact form
- Agree terms under the all-included leasing model and check the reimbursement code that applies in your country
- Have the platform installed and your team trained: neuroClues supports the whole implementation process
- Set the Lab on its stand and connect the dedicated computer running the App to it
- Select the protocols matching your clinical question, or load a pre-built set of protocols
- Seat the patient in the cone in an ecological posture, wheelchair included, with no calibration step
- Run the recording: about ten minutes, and delegable to an assistant or a nurse
- Review the computed biomarkers, timecourses and eye-movement videos against the reference ranges
- Add your clinical observations and generate the PDF patient report
- File the subject in a project, share it with other healthcare professionals and follow results over time
Pros & Cons
Pros
- Genuine regulatory standing: CE-marked class IIa under MDR since January 2025, backed by ISO 13485:2016 and ISO 27001:2022
- A short exam of around ten minutes that can be delegated to an assistant or a nurse, so it costs little consultation time
- Covered by an existing reimbursement code in several countries, France and Belgium included
- No patient calibration, fast setup, portable between rooms, wheelchair-compatible and usable from age five
- Results are interpretable rather than raw: literature-derived reference ranges sit next to every biomarker
- Real clinical adoption, with more than 30 devices across seven European countries, the Iceberg cohort and a 25,000-participant study
- Maintenance included in the offer, local technicians in France and Belgium, 24-hour technical response and intervention within five days
Cons
- No public pricing at all: no pricing page, no figure, no tier, everything runs through a demo and a sales conversation
- No terms and conditions are published; the only contractual document online is the data protection policy
- Commercial availability is limited to the European Union while regulatory approvals are pending elsewhere
- Pseudonymised patient data feeds algorithm training under legitimate interest, the policy's rights section does not cover it, and no opt-out is documented
- No DPA and no named subprocessor list, which is a lot left unsaid for health data
- Requires dedicated hardware and a dedicated computer, with an accompanied implementation rather than a self-service install
- Broad scientific validation is still announced rather than delivered: one neurologist quoted on the site conditions wide adoption on a study yet to run
Pricing & Plans
No permanent free plan and no free trial are offered, and no price is published. neuroClues is commercialised through an all-included leasing arrangement with maintenance covered, and access begins with a 30-minute demo followed by a sales conversation. The lowest paid entry point is therefore not public, and neither a currency nor a billing period is stated. The company does note that in several countries, including France and Belgium, the electro-oculography procedure is covered by existing reimbursement codes, with amounts varying by country.
Data, GDPR & hosting
A consolidated view of how neuroClues handles your data.
GDPR overview
Compliance is claimed in so many words: the homepage FAQ states that neuroClues is GDPR-compliant and the product page labels the cloud layer GDPR compliant. A Data Protection Policy version 3.0 dated March 2026 is published, a Data Protection Officer is named and reachable at dpo@p3lab.com in Louvain-la-Neuve, legal bases are set out purpose by purpose, and eight data subject rights are listed alongside the Belgian Data Protection Authority as supervisory body. The company holds ISO 27001:2022 for information security and ISO 13485:2016 for quality management. One reservation is stated in the policy itself: those rights do not apply to the two processing activities carried out on pseudonymised patient data. No DPA is offered and no subprocessor is named.
Who owns the data?
No terms and conditions are published, so ownership is addressed only in the Data Protection Policy (version 3.0, March 2026) and the regulatory disclaimer. P3Lab acts as controller for client, prospect, supplier, participant and applicant data, and as a processor on behalf of its clinical customers for patient data captured by the device. It additionally keeps a pseudonymised copy for its own purposes: demographics, eye-movement timecourses, biomarker values, recorded videos and clinical evaluation data. Data may be shared with staff, subcontractors, courts and other judicial actors, independent consultants, authorities and legal-assistance insurers. Website content and the neuroClues trademark remain P3Lab property and may not be reproduced without consent.
Reuse rights
What a clinical customer may do with the exam data it produces is not stated anywhere, because no terms and conditions exist. The product pages describe practice rather than rights: results stay attached to each subject profile for longitudinal follow-up, subjects are organised into anonymous projects that can be securely shared with other healthcare professionals, biomarkers are stored in the cloud and remain reachable even if the local system fails, and the app generates a PDF report combining quantitative data with the clinician's own notes. On the vendor side, reuse is explicit and requires no permission from the individual: pseudonymised patient data feeds algorithm training and biomarker statistical models under legitimate interest. Any buyer needing clear reuse or portability rights should secure them contractually before deployment.
Data retention & training
Hosting summary
Hosting follows the customer's location. The data protection policy states that servers are in the European Union for EU-based clients and in the United States for US-based clients, and commits to keeping data originating from the EU within the EU and data originating from the US within the US. The homepage FAQ adds that neuroClues relies on EU-based providers for secure storage of EU customers' data. The neuroClues Cloud is the remote database behind the product: biomarkers are stored there and stay reachable even if the local system fails, and it supports multi-user, multi-site work. Security is claimed to be built into every layer by default and by design, and the company obtained ISO 27001:2022 certification in April 2026. The controller is P3Lab, Belgian company number 0750.746.841, and the competent supervisory authority is the Belgian Data Protection Authority. Two things go unsaid: no hosting provider is named and no subprocessor list is published. The domain's public IP resolves to a content delivery network node and says nothing about where health data actually sits.
Where neuroClues works
Country-level availability.
Not available in
Things to keep in mind
Risks and trade-offs to weigh before adopting neuroClues.
- Pseudonymised patient recordings, including eye-movement videos and clinical evaluation data, are used to train the vendor's algorithm under legitimate interest, and no opt-out is documented
- The privacy policy states that the listed data subject rights do not apply to those training and modelling activities, because P3Lab considers the data unlinkable to an individual
- A quantified number invites more confidence than it deserves: the site itself insists interpretation must be guided by the clinical question and placed within the wider neurological examination
- Used as a substitute rather than a complement, an automated test can erode the very examination skills it was meant to extend
- No terms and conditions, no DPA and no subprocessor list are published, so obligations, warranties and liability stay invisible until contracting
- Retention runs to ten years depending on the relationship, and no duration at all is stated for the pseudonymised research data
- The site declares its own content purely informational and demonstrative, with no warranty as to accuracy, completeness or currency
Setup & Integrations
Technical difficulty
Low for the clinician. The platform is presented as plug-and-play: no patient calibration, fast setup, portable from room to room, and the App runs on a dedicated computer already wired to the Lab. Acquisition can be delegated to an assistant or a nurse, neuroClues supports the whole implementation and trains the team, maintenance is included with local technicians in France and Belgium, and software updates arrive remotely through the Cloud. The real effort is organisational rather than technical: acquiring hardware, signing a leasing agreement and settling reimbursement coding. Nothing has to be developed, since there is no API to integrate.
Deployment
Behind neuroClues
Fundraising
Social
Resources
All the official URLs gathered for verification and reference.
Frequently asked questions
Is neuroClues a certified medical device?
How long does an examination take, and who performs it?
What equipment does it require?
How much does it cost?
Is the procedure reimbursed?
Where is it available?
Where is the data hosted?
Is patient data used to train the AI?
Is there a mobile application?
How long is data kept?
Should you pick neuroClues?
neuroClues sets out to do something narrow and do it properly: turn a century of oculomotor research into a ten-minute exam a neurologist can run between two consultations. The regulatory groundwork is real, with CE marking as a class IIa medical device under MDR since January 2025, an ISO 13485:2016 quality system and ISO 27001:2022 for information security. So is the early traction: more than thirty devices deployed across seven European countries, a place in the Paris Brain Institute's Iceberg cohort and a 25,000-participant normative study. The design choices show the same discipline, from the absence of patient calibration to a wheelchair-compatible stand, an acquisition explicitly delegable to a nurse, and results presented against literature-derived reference ranges rather than as raw numbers.
The reservations deserve equal weight. Nothing about the commercial side is public, so a buyer discovers price and contract only after entering a sales conversation. On data, the policy is unusually candid and that candour cuts both ways: pseudonymised patient recordings, videos included, feed algorithm training under legitimate interest, the stated data subject rights explicitly do not cover that processing, and no opt-out, DPA or subprocessor list exists. For health data, that is a lot left unsaid. The company's own clinical champions are careful too: one of the neurologists quoted on the site backs the concept but conditions wide adoption on a study still to be launched.
For a neurology department, a movement-disorder clinic or a research group already convinced by oculomotor biomarkers, neuroClues is one of the few options that is both certified and shipping today. For everyone else, the demo is the only way to learn what it actually costs.
- Choosing a selection results in a full page refresh.
- Opens in a new window.